Statin therapy in venous thromboembolism: How far from primary and secondary prevention?

J Thromb Haemost. 2022 Aug;20(8):1781-1783. doi: 10.1111/jth.15752.

Authors

Rong Jiang¹, Zhi-Cheng Jing^{1

2}

Affiliations

¹ Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
² Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

PMID: 35859281
DOI: 10.1111/jth.15752

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
Risk Factors
Secondary Prevention
Venous Thromboembolism* / diagnosis
Venous Thromboembolism* / drug therapy
Venous Thromboembolism* / prevention & control

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors